Charles Schwab’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.5M Buy
732,042
+55,690
+8% +$1.24M ﹤0.01% 1852
2025
Q4
$17.5M Buy
676,352
+49,079
+8% +$1.17M ﹤0.01% 1836
2025
Q3
$16.2M Buy
627,273
+57,194
+10% +$1.4M ﹤0.01% 1863
2025
Q2
$13.6M Buy
570,079
+45,593
+9% +$1.15M ﹤0.01% 1860
2025
Q1
$13M Buy
524,486
+22,282
+4% +$533K ﹤0.01% 1833
2024
Q4
$9.46M Buy
502,204
+70,307
+16% +$1.23M ﹤0.01% 2041
2024
Q3
$6.5M Buy
431,897
+16,819
+4% +$288K ﹤0.01% 2239
2024
Q2
$11.9M Buy
415,078
+927
+0.2% +$26.4K ﹤0.01% 1956
2024
Q1
$12.1M Buy
414,151
+42,485
+11% +$1.31M ﹤0.01% 1898
2023
Q4
$12.5M Buy
371,666
+11,696
+3% +$342K ﹤0.01% 1869
2023
Q3
$11M Buy
359,970
+11,453
+3% +$413K ﹤0.01% 1863
2023
Q2
$14M Buy
348,517
+633
+0.2% +$26.2K ﹤0.01% 1732
2023
Q1
$14.2M Buy
347,884
+6,880
+2% +$274K ﹤0.01% 1701
2022
Q4
$13.2M Buy
341,004
+9,229
+3% +$449K ﹤0.01% 1698
2022
Q3
$17.6M Buy
331,775
+10,632
+3% +$591K 0.01% 1458
2022
Q2
$18.7M Sell
321,143
-27,705
-8% -$1.81M 0.01% 1459
2022
Q1
$26.6M Sell
348,848
-10,720
-3% -$715K 0.01% 1320
2021
Q4
$21.6M Buy
359,568
+18,508
+5% +$1.02M 0.01% 1519
2021
Q3
$19.1M Buy
341,060
+19,642
+6% +$1.13M 0.01% 1629
2021
Q2
$19.5M Buy
321,418
+5,810
+2% +$368K 0.01% 1607
2021
Q1
$22.1M Sell
315,608
-20,321
-6% -$1.45M 0.01% 1449
2020
Q4
$20.1M Buy
335,929
+3,235
+1% +$189K 0.01% 1404
2020
Q3
$20M Sell
332,694
-21,389
-6% -$1.24M 0.01% 1201
2020
Q2
$18.6M Buy
354,083
+13,390
+4% +$560K 0.01% 1236
2020
Q1
$11.4M Buy
340,693
+4,864
+1% +$202K 0.01% 1375
2019
Q4
$15.2M Buy
335,829
+7,801
+2% +$331K 0.01% 1403
2019
Q3
$12.5M Buy
328,028
+29,699
+10% +$1.19M 0.01% 1464
2019
Q2
$13M Buy
298,329
+10,153
+4% +$431K 0.01% 1426
2019
Q1
$11M Buy
288,176
+30,783
+12% +$1.2M 0.01% 1531
2018
Q4
$11.1M Buy
257,393
+16,639
+7% +$777K 0.01% 1389
2018
Q3
$11.8M Buy
240,754
+27,530
+13% +$1.19M 0.01% 1527
2018
Q2
$6.83M Buy
213,224
+17,950
+9% +$620K 0.01% 1840
2018
Q1
$6.08M Buy
195,274
+8,025
+4% +$286K ﹤0.01% 1836
2017
Q4
$8.55M Sell
187,249
-1,428
-0.8% -$56.6K 0.01% 1593
2017
Q3
$7.08M Buy
188,677
+9,977
+6% +$401K 0.01% 1690
2017
Q2
$8.52M Buy
178,700
+13,973
+8% +$648K 0.01% 1475
2017
Q1
$7.51M Buy
164,727
+3,015
+2% +$130K 0.01% 1510
2016
Q4
$5.22M Buy
161,712
+33,272
+26% +$1.11M 0.01% 1717
2016
Q3
$4.4M Buy
128,440
+6,012
+5% +$236K 0.01% 1735
2016
Q2
$4.13M Sell
122,428
-9,182
-7% -$451K 0.01% 1690
2016
Q1
$6.97M Buy
131,610
+1,645
+1% +$96.2K 0.01% 1297
2015
Q4
$9.98M Buy
129,965
+3,703
+3% +$210K 0.01% 1024
2015
Q3
$5.19M Buy
126,262
+8,522
+7% +$522K 0.01% 1445
2015
Q2
$8.33M Buy
117,740
+3,269
+3% +$257K 0.01% 1180
2015
Q1
$10.2M Buy
114,471
+6,776
+6% +$687K 0.01% 984
2014
Q4
$9.55M Buy
107,695
+1,130
+1% +$107K 0.01% 927
2014
Q3
$10.3M Buy
106,565
+14,018
+15% +$1.36M 0.02% 802
2014
Q2
$8.5M Buy
92,547
+11,642
+14% +$886K 0.01% 966
2014
Q1
$5.66M Buy
80,905
+4,457
+6% +$303K 0.01% 1233
2013
Q4
$4.39M Buy
76,448
+3,165
+4% +$166K 0.01% 1373
2013
Q3
$3.73M Buy
73,283
+10,772
+17% +$393K 0.01% 1412
2013
Q2
$1.84M Buy
+62,511
New +$1.81M ﹤0.01% 1815

Other funds holding PCRX